Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.
about
From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cellsDifferential ErbB1 signaling in squamous cell versus basal cell carcinoma of the skinMolecular Portrait of the Normal Human Breast Tissue and Its Influence on Breast CarcinogenesisNovel approaches to target HER2-positive breast cancer: trastuzumab emtansineA paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapyMultifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilitiesCellular immunotherapy for pediatric solid tumorsAntibody Drug Conjugates: Preclinical ConsiderationsSelective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptorRecent advances in the development of anti-HER2 antibodies and antibody-drug conjugatesDifferential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytesGenome-wide association study identifies NRG1 as a susceptibility locus for Hirschsprung's diseaseCase report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targetingHigh-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)--mediated inhibition of platelet production.Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials.Palmitoylation: a protein S-acylation with implications for breast cancer.Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay.Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trialDriving CAR T-cells forwardOptimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.Neu differentiation factor upregulates epidermal migration and integrin expression in excisional wounds.Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potentialThe oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisIn vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas.Development of anti-p185HER2 immunoliposomes for cancer therapyInhibition of the erbB-2 tyrosine kinase receptor in breast cancer cells by phosphoromonothioate and phosphorodithioate antisense oligonucleotides.Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivoHeterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation.Chemotherapy for breast cancer in pregnancy: evidence and guidance for oncologists.EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides.Targeted therapy in her2-positive metastatic breast cancer: a review of the literature.A transductionally retargeted adenoviral vector for virotherapy of Her2/neu-expressing prostate cancer.Selection of potentially metastatic subpopulations expressing c-erbB-2 from breast cancer tissue by use of an extravasation model.Development of hyperplasias, preneoplasias, and mammary tumors in MMTV-c-erbB-2 and MMTV-TGFalpha transgenic rats.Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade gliomaAntibody Drug Conjugates: Nonclinical Safety Considerations.Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growthAffinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice
P2860
Q24682910-34CC3BA8-F6E9-4D6C-A794-D40F67D851E1Q24683791-62EFBEAE-9807-4445-9292-F14CF26D17EAQ26744296-4E5F18D3-3B7C-4BB9-A1E9-1710D8F3A9E7Q26747729-96A4B77C-1AC8-4831-B1E4-3F51C8E8A751Q26824462-7A70BBAF-DD9E-40AD-BCC1-4C93B664DEE0Q27011598-55BC436E-88A8-457D-9D87-DA9891326077Q27014912-3C01EE14-1973-467E-A2DC-A8E6A083A397Q27022321-4C976C58-9BDF-4A47-A1C3-3AC34BA17CAAQ27318470-E12031B3-822A-4BDE-997E-47AACA48219FQ28083123-9362EA2A-81D9-4A92-BF25-B03B8A3B1D14Q28360375-E1A5247C-E9CA-4A6E-95C5-68725765061AQ28943464-D15BAF65-4990-4331-AFBB-BB69753D4A10Q29620608-18FDB1EE-3B89-47AA-B8D2-A2A356AC091AQ30456053-47A6FCDF-5638-45E3-9E7A-E76D6242CB01Q30524836-777E2B08-0A3C-4863-A2AA-95CEB946E4BBQ33661325-18B26164-64DD-43F9-ADDC-4BBAFD70BE10Q33915087-0B9C5BE8-C248-46A4-8921-B12395855475Q33970193-E2616DB0-2B51-4345-8C35-6C6E171D5BC6Q33991804-2E815575-CB26-4635-90F2-9722AC8245B5Q34046505-4C4B2CB0-A78D-483A-891A-E77968F1E1CCQ34164704-E9D4DCC9-3DCF-42F5-BAB8-220427A40EB0Q34203118-1FD4FC62-8650-4DF8-864B-42B95D74E8EDQ34389275-ECBC73AB-9BE3-4B4E-BC98-FBB7D6039263Q34493341-B5DE7EA8-5ED0-4BBE-99CD-F47E09615C6DQ34519479-74EDF7A1-F60A-4F29-A6F3-0EA5550585AAQ34607767-A92C29C4-8BA0-4F1F-958F-A63813BC2FE2Q34618574-6787B568-E3DA-47F7-97F2-D909ACDCCAD7Q34655256-D800208C-151A-43E8-9EE5-C02D6685C74EQ34787422-C6E964CA-EDD6-4ECD-B3F2-821E52CA6EECQ35054357-7DEB046B-94D1-4FB6-96EB-0ADEA64C23CFQ35076343-AA04729F-4EC0-4BD5-85D6-4FBE4A0928B9Q35184816-08692D26-4E27-4FC1-96C8-B57742CF16F0Q35239603-AAFE6F22-FBD8-4E38-A8AA-1787C155624CQ35678429-1C01AF4A-51C3-4CFC-896B-2F73E7EAD6A6Q35785948-0CC280F7-ED3A-4930-8C9D-94A6D895511DQ35787289-41BDB621-FC18-43FB-A2FB-6BCDD6E415FDQ35939421-A466DCC3-A431-459B-8A09-9D626DE152BDQ35967917-267CDEC1-544B-4B1D-9D91-0B57803D2F43Q35977584-8647EE3B-065B-4913-B546-0AE3A2D6B4C1Q36028047-6A791F05-040F-4CFF-BF44-0901B35BBD57
P2860
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh-hant
name
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.
@en
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.
@nl
type
label
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.
@en
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.
@nl
prefLabel
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.
@en
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.
@nl
P2093
P1433
P1476
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.
@en
P2093
Cordon-Cardo C
P304
P407
P577
1990-07-01T00:00:00Z